Deutsch English Français

Contact

EP2870172

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2870172

EP2870172 - EXTRACELLULAR MATRIX HEPARIN-BINDING DOMAINS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 12.05.2017 Database last updated on 31.08.2024
Former	Examination is in progress Status updated on 31.01.2017
Most recent event Tooltip	12.05.2017	Application deemed to be withdrawn	published on 14.06.2017 [2017/24]
Applicant(s)	For all designated states École Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO EPFL Innovation Park J 1015 Lausanne / CH
	[N/P]
Former [2015/20]	For all designated states Ecole Polytechnique Fédérale de Lausanne (EPFL) EPFL-TTO EPFL Innovation Park J 1015 Lausanne / CH
Inventor(s)	01 / HUBBELL, Jeffrey A. 4837 South Kimbark Avenue Chicago, IL 60615-1915 / UA
	02 / MARTINO, Mikaël Ch. de la Redoute 20 CH-1260 Nyon / CH
	03 / DE LAPORTE, Laura Konig Albertlaan 12 B-9840 De Pinte / BE
	04 / RICE, Jeffrey J. 1498 Parkway Drive Cookeville, TN 35801 / US
	05 / TORTELLI, Federico Hebelplatz 3 CH-4056 Basel / CH
	[2015/24]
Former [2015/20]	01 / HUBBELL, Jeffrey A. 4837 South Kimbark Avenue Chicago, IL 60615-1915 / UA
	02 / MARTINO, Mikaël Ch. de la Redoute 20 CH-1260 Nyon / CH
	03 / DE LAPORTE, Laura Konig Albertlaan 12 B-9840 De Pinte / BE
	04 / RICE, Jeffrey J. 1498 Parkway Drive Cookeville, TN 35801 / US
	05 / TORTELLI, Federico Av d-Echallens 56 CH-1004 Lausanne / CH
Representative(s)	dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE
	[N/P]
Former [2015/20]	Von Kreisler Selting Werner - Partnerschaft von Patentanwälten und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln / DE
Application number, filing date	13732977.7	03.07.2013
	WO2013EP64023
Priority number, date	US201261667634P	03.07.2012 Original published format: US 201261667634 P
	[2015/20]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2014006087
	Date:	09.01.2014
	Language:	EN
	[2014/02]
	Type:	A1 Application with search report
	No.:	EP2870172
	Date:	13.05.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 09.01.2014 takes the place of the publication of the European patent application.
	[2015/20]
Search report(s)	International search report - published on:	EP	09.01.2014
Classification	IPC:	C07K14/315	[2015/20]
	CPC:	C07K14/75 (EP,US); C07K14/4718 (US); C07K14/78 (EP,US); C07K2319/00 (EP,US)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2015/20]
Title	German:	EXTRAZELLULÄRE MATRIX MIT HEPARINBINDENDEN DOMÄNEN	[2015/20]
	English:	EXTRACELLULAR MATRIX HEPARIN-BINDING DOMAINS	[2015/20]
	French:	DOMAINES DE LIAISON À L'HÉPARINE DE MATRICE EXTRACELLULAIRE	[2015/20]
Entry into regional phase	29.01.2015	National basic fee paid
	29.01.2015	Designation fee(s) paid
	29.01.2015	Examination fee paid
Examination procedure	29.01.2015	Examination requested [2015/20]
	15.10.2015	Amendment by applicant (claims and/or description)
	22.06.2016	Despatch of a communication from the examining division (Time limit: M06)
	03.01.2017	Application deemed to be withdrawn, date of legal effect [2017/24]
	01.02.2017	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2017/24]
Divisional application(s)	EP16206356.4 / EP3202781
	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.06.2016
Fees paid	Renewal fee
	27.07.2015	Renewal fee patent year 03
	27.09.2016	Renewal fee patent year 04
	Penalty fee
	Additional fee for renewal fee
	31.07.2016	04 M06 Fee paid on 27.09.2016
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited in	International search	[X]WO03048185 (GENVEC INC [US], et al) [X] 1-49 * claim -; sequence 136 *;
		[X]KR20060005595 (SEOUL NAT UNIV IND FOUNDATION [KR]) [X] 1-49 * the whole document *;
		[A]WO2009038729 (REGENERX BIOPHARMACEUTICALS [US], et al) [A] 1-49 * the whole document *;
		[XP] - LAURA DE LAPORTE ET AL, "Tenascin C Promiscuously Binds Growth Factors via Its Fifth Fibronectin Type III-Like Domain", PLOS ONE, (20130101), vol. 8, no. 4, doi:10.1371/journal.pone.0062076, ISSN 1932-6203, pages e62076 - e62076, XP055077343 [XP] 1-49 * the whole document * DOI: http://dx.doi.org/10.1371/journal.pone.0062076
	by applicant	US5227165
		US6022564
		US6090925
		US6224794
		US6331422
		US6607740
		US6723344
		US7241730
		US2007202178
		US2007264227
		US2008031899
		US2010003338
		US2010055189
		- J. BIOL. CHEM., (1969), vol. 243, pages 3552 - 3559
		- LUTOLF; HUBBELL, BIOMACROMOLECULES, (2003), vol. 4, pages 713 - 22
		- DEVALAPALLY ET AL., CANCER CHEMOTHER PHARMACOL.
		- LANGER ET AL., INTERNATIONAL JOURNAL OF PHARMACEUTICS, (2003), vol. 257, pages 169 - 180
		- TOBIO ET AL., PHARMACEUTICAL RESEARCH, (1998), vol. 15, no. 2, pages 270 - 275
		- SCHONHERR E; HAUSSER HJ, "Extracellular matrix and cytokines: a functional unit", DEVELOPMENTAL IMMUNOLOGY, (2000), vol. 7, no. 2-4, pages 89 - 101
		- MARTINO MM; HUBBELL JA, "The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain", THE FASEB JOURNAL: OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, (2010), vol. 24, no. 12, pages 4711 - 4721
		- MARTINO MM; TORTELLI F; MOCHIZUKI M; TRAUB S; BEN-DAVID D; KUHN GA; MULLER R; LIVNE E; EMING SA; HUBBELL JA, "Engineering the growth factor microenvironment with fibronectin domains to promote wound and bone tissue healing", SCIENCE TRANSLATIONAL MEDICINE, (2011), vol. 3, no. 100, page 100RA189
		- KLEINMAN HK; PHILP D; HOFFMAN MP, "Role of the extracellular matrix in morphogenesis", CURR OPIN BIOTECHNOL, (2003), vol. 14, no. 5, pages 526 - 532
		- DISCHER DE; MOONEY DJ; ZANDSTRA PW, "Growth factors, matrices and forces combine and control stem cells", SCIENCE, (2009), vol. 324, pages 1673 - 1677
		- BERRIER AL; YAMADA KM, "Cell-matrix adhesion", J CELL PHYSIOL, (2007), vol. 213, pages 565 - 573
		- SCHULTZ GS; WYSOCKI A, "Interactions between extracellular matrix and growth factors in wound healing", WOUND REPAIR REGEN, (2009), vol. 17, pages 153 - 162
		- LINDAHL U; LI JP, "Interactions between heparan sulfate and proteins - design and functional implications", INT REV CELL MOLEC BIOL, (2009), vol. 276, pages 105 - 159
		- MAKARENKOVA HP; HOFFMAN MP; BEENKEN A; ELISEENKOVA AV; MEECH R; TASAU C; PATEL VN; LANG RA; MOHAMMADI M, "Differential interactions of FGFs with heparan sulfate control gradient formation and branching morphogenesis", SCI SIGNAL, (2009), vol. 2, page RA55
		- TREBAUL A; CHAN EK; MIDWOOD KS, "Regulation of fibroblast migration by tenascin-C", BIOCHEM SOC TRANS, (2007), vol. 35, pages 695 - 697
		- OREND G, "Potential oncogenic action of tenascin-C in tumorigenesis", INT J BIOCHEM CELL BIOL, (2005), vol. 37, no. 5, pages 1066 - 1083
		- UDALOVA IA; RUHMANN M; THOMSON SJ; MIDWOOD KS, "Expression and immune function of tenascin-C", CRIT REV IMMUNOL, (2011), vol. 31, no. 2, pages 115 - 145
		- JONES FS; JONES PL, "The tenascin family of ECM glycoproteins: structure, function, and regulation during embryonic development and tissue remodeling", DEV DYN, (2000), vol. 218, no. 2, pages 235 - 259
		- JOESTER A; FAISSNER A, "The structure and function of tenascins in the nervous system", MATRIX BIOL, (2001), vol. 20, no. 1, pages 13 - 22
		- IMANAKA-YOSHIDA K; MATSUURA R; ISAKA N; NAKANO T; SAKAKURA T; YOSHIDA T, "Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin- C expression", VIRCHOWS ARCH, (2001), vol. 439, no. 2, pages 185 - 190
		- GOLLEDGE J; CLANCY P; MAGUIRE J; LINCZ L; KOBLAR S, "The role of tenascin C in cardiovascular disease", CARDIOVASC RES, (2011), vol. 92, no. 1, pages 19 - 28
		- O'CONNELL JT; SUGIMOTO H; COOKE VG; MACDONALD BA; MEHTA AI; LEBLEU VS; DEWAR R; ROCHA RM; BRENTANI RR; RESNICK MB, "VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization", PROC NATL ACAD SCI USA, (2011), vol. 108, no. 38, pages 16002 - 16007
		- OSKARSSON T; ACHARYYA S; ZHANG XH; VANHARANTA S; TAVAZOIE SF; MORRIS PG; DOWNEY RJ; MANOVA-TODOROVA K; BROGI E; MASSAGUE J, "Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs", NAT MED, (2011), vol. 17, no. 7, pages 867 - 874
		- MIDWOOD KS; HUSSENET T; LANGLOIS B; OREND G, "Advances in tenascin-C biology", CELL MOL LIFE SCI, (2011), vol. 68, no. 19, pages 3175 - 3199
		- WEISEL JW, "Structure of fibrin: impact on clot stability", JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH, (2007), vol. 5, no. 1, pages 116 - 124
		- MOSESSON MW, "Fibrinogen and fibrin structure and functions", JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH, (2005), vol. 3, no. 8, pages 1894 - 1904
		- UGAROVA TP; YAKUBENKO VP, "Recognition of fibrinogen by leukocyte integrins", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (2001), vol. 936, pages 368 - 385
		- FLICK MJ; DU X; WITTE DP; JIROUSKOVA M; SOLOVIEV DA; BUSUTTIL SJ; PLOW EF; DEGEN JL, "Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo", THE JOURNAL OF CLINICAL INVESTIGATION, (2004), vol. 113, no. 11, pages 1596 - 1606
		- JANMEY PA; WINER JP; WEISEL JW, "Fibrin gels and their clinical and bioengineering applications", JOURNAL OF THE ROYAL SOCIETY, INTERFACE / THE ROYAL SOCIETY, (2009), vol. 6, no. 30, pages 1 - 10
		- LORAND L; GRAHAM RM, "Transglutaminases: crosslinking enzymes with pleiotropic functions", NATURE REVIEWS. MOLECULAR CELL BIOLOGY, (2003), vol. 4, no. 2, pages 140 - 156
		- STANDEVEN KF; CARTER AM; GRANT PJ; WEISEL JW; CHERNYSH I; MASOVA L; LORD ST; ARIENS RA, "Functional analysis of fibrin {gamma}-chain cross-linking by activated factor XIII: determination of a cross-linking pattern that maximizes clot stiffness", BLOOD, (2007), vol. 110, no. 3, pages 902 - 907
		- WEISEL JW, "The mechanical properties of fibrin for basic scientists and clinicians", BIOPHYS CHEM, (2004), vol. 112, no. 2-3, pages 267 - 276
		- SCHENSE JC; HUBBELL JA, "Cross-linking exogenous bifunctional peptides into fibrin gels with factor XIIIa", BIOCONJUG CHEM, (1999), vol. 10, no. 1, pages 75 - 81
		- PATTERSON J; MARTINO MM; HUBBELL JA, "Biomimetic materials in tissue engineering", MATERIALS TODAY, (2010), vol. 13, no. 1-2, pages 14 - 22
		- SAHNI A; KHORANA AA; BAGGS RB; PENG H; FRANCIS CW, "FGF-2 binding to fibrin(ogen) is required for augmented angiogenesis", BLOOD, (2006), vol. 107, no. 1, pages 126 - 131
		- PENG H; SAHNI A; FAY P; BELLUM S; PRUDOVSKY I; MACIAG T; FRANCIS CW, "Identification of a binding site on human FGF-2 for fibrinogen", BLOOD, (2004), vol. 103, no. 6, pages 2114 - 2120
		- WERNER S; GROSE R, "Regulation of wound healing by growth factors and cytokines", PHYSIOLOGICAL REVIEWS, (2003), vol. 83, no. 3, pages 835 - 870
		- SAHNI A; ODRLJIN T; FRANCIS CW, "Binding of basic fibroblast growth factor to fibrinogen and fibrin", JOURNAL OF BIOLOGICAL CHEMISTRY, (1998), vol. 273, no. 13, pages 7554 - 7559
		- KRAMMER A; CRAIG D; THOMAS WE; SCHULTEN K; VOGEL V, "A structural model for force regulated integrin binding to fibronectin's RGD-synergy site", MATRIX BIOL, (2002), vol. 21, no. 2, pages 139 - 147
		- MAO Y; SCHWARZBAUER JE, "Fibronectin fibrillogenesis, a cell-mediated matrix assembly process", MATRIX BIOL, (2005), vol. 24, no. 6, pages 389 - 399
		- PANKOV R; YAMADA KM, "Fibronectin at a glance", J CELL SCI, (2002), vol. 115, pages 3861 - 3863
		- UPTON Z; WEBB H; HALE K; YANDELL CA; MCMURTRY JP; FRANCIS GL; BALLARD FJ, "Identification of vitronectin as a novel insulin-like growth factor-II binding protein", ENDOCRINOLOGY, (1999), vol. 140, no. 6, pages 2928 - 2931
		- KRICKER JA; TOWNE CL; FIRTH SM; HERINGTON AC; UPTON Z, "Structural and functional evidence for the interaction of insulin-like growth factors (IGFs) and IGF binding proteins with vitronectin", ENDOCRINOLOGY, (2003), vol. 144, no. 7, pages 2807 - 2815
		- SCHOPPET M; CHAVAKIS T; AL-FAKHRI N; KANSE SM; PREISSNER KT, "Molecular interactions and functional interference between vitronectin and transforming growth factor- beta", LAB INVEST, (2002), vol. 82, no. 1, pages 37 - 46
		- LEAHY DJ; HENDRICKSON WA; AUKHIL I; ERICKSON HP, "Structure of a fibronectin type III domain from tenascin phased by MAD analysis of the selenomethionyl protein", SCIENCE, (1992), vol. 258, no. 5084, pages 987 - 991
		- PENG Q; ZHUANG S; WANG M; CAO Y; KHOR Y; LI H, "Mechanical design of the third FnIII domain oftenascin-C", JOURNAL OF MOLECULAR BIOLOGY, (2009), vol. 386, no. 5, pages 1327 - 1342
		- YOKOSAKI Y; MATSUURA N; HIGASHIYAMA S; MURAKAMI I; OBARA M; YAMAKIDO M; SHIGETO N; CHEN J; SHEPPARD D, "Identification of the ligand binding site for the integrin alpha9 betal in the third fibronectin type III repeat of tenascin-C", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (1998), vol. 273, no. 19, pages 11423 - 11428
		- WEBER P; ZIMMERMANN DR; WINTERHALTER KH; VAUGHAN L, "Tenascin-C binds heparin by its fibronectin type III domain five", J BIOL CHEM, (1995), vol. 270, no. 9, pages 4619 - 4623
		- WEISEL JW; STAUFFACHER CV; BULLITT E; COHEN C, "A model for fibrinogen: domains and sequence", SCIENCE, (1985), vol. 230, no. 4732, pages 1388 - 1391
		- ODRLJIN TM; SHAINOFF JR; LAWRENCE SO; SIMPSON-HAIDARIS PJ, "Thrombin cleavage enhances exposure of a heparin binding domain in the N-terminus of the fibrin beta chain", BLOOD, (1996), vol. 88, no. 6, pages 2050 - 2061
		- MARDON HJ; GRANT KE, "The role of the ninth and tenth type III domains of human fibronectin in cell adhesion", FEBS LETT, (1994), vol. 340, no. 3, pages 197 - 201
	- MOULD AP; ASKARI JA; AOTA S; YAMADA KM; IRIE A; TAKADA Y; MARDON HJ; HUMPHRIES MJ, "Defining the topology of integrin alpha5betal-fibronectin interactions using inhibitory anti-alpha5 and anti-beta monoclonal antibodies. Evidence that the synergy sequence of fibronectin is recognized by the amino-terminal repeats of the alpha5 subunit", J BIOL CHEM, (1997), vol. 272, no. 28, pages 17283 - 17292
	- DANEN EH; AOTA S; VAN KRAATS AA; YAMADA KM; RUITER DJ; VAN MUIJEN GN, "Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta I", J BIOL CHEM, (1995), vol. 270, no. 37, pages 21612 - 21618
	- VAN DER WALLE CF; ALTROFF H; MARDON HJ, "Novel mutant human fibronectin FIII9-10 domain pair with increased conformational stability and biological activity", PROTEIN ENGINEERING, (2002), vol. 15, no. 12, pages 1021 - 1024
	- GURTNER GC; WERNER S; BARRANDON Y; LONGAKER MT, "Wound repair and regeneration", NATURE, (2008), vol. 453, no. 7193, pages 314 - 321
	- HERBERT SP; STAINIER DY, "Molecular control of endothelial cell behaviour during blood vessel morphogenesis", NATURE REVIEWS. MOLECULAR CELL BIOLOGY, (2011), vol. 12, no. 9, pages 551 - 564
	- KARP JM; LENG TEO GS, "Mesenchymal stem cell homing: the devil is in the details", CELL STEM CELL, (2009), vol. 4, no. 3, pages 206 - 216
	- EMING SA; HAMMERSCHMIDT M; KRIEG T; ROERS A, "Interrelation of immunity and tissue repair or regeneration", SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, (2009), vol. 20, no. 5, pages 517 - 527
	- LUTOLF MP; HUBBELL JA, "Synthetic biomaterials as instructive extracellular microenvironments for morphogenesis in tissue engineering", NAT BIOTECHNOL, (2005), vol. 23, no. 1, pages 47 - 55
	- ATALA A, "Advances in tissue and organ replacement", CURR STEM CELL RES THER, (2008), vol. 3, no. 1, pages 21 - 31
	- HUEBSCH N; MOONEY DJ, "Inspiration and application in the evolution of biomaterials", NATURE, (2009), vol. 462, no. 7272, pages 426 - 432
	- AFFOLTER M; BASLER K, "The Decapentaplegic morphogen gradient: from pattern formation to growth regulation", NATURE REVIEWS. GENETICS, (2007), vol. 8, no. 9, pages 663 - 674
	- VILCEK J; FELDMANN M, "Historical review: Cytokines as therapeutics and targets of therapeutics", TRENDS IN PHARMACOLOGICAL SCIENCES, (2004), vol. 25, no. 4, pages 201 - 209
	- CROSS M; DEXTER TM, "Growth factors in development, transformation, and tumorigenesis", CELL, (1991), vol. 64, no. 2, pages 271 - 280
	- OVIEDO NJ; BEANE WS, "Regeneration: The origin of cancer or a possible cure?", SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, (2009), vol. 20, no. 5, pages 557 - 564
	- SCHAFER M; WERNER S, "Cancer as an overhealing wound: an old hypothesis revisited", NATURE REVIEWS. MOLECULAR CELL BIOLOGY, (2008), vol. 9, no. 8, pages 628 - 638
	- WRZESINSKI SH; WAN YY; FLAVELL RA, "Transforming growth factor-beta and the immune response: implications for anticancer therapy", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, (2007), vol. 13, no. 18, pages 5262 - 5270
	- BIERIE B; MOSES HL, "Transforming growth factor beta (TGF-beta) and inflammation in cancer", CYTOKINE & GROWTH FACTOR REVIEWS, (2010), vol. 21, no. 1, pages 49 - 59
	- UNTERGASSER G; GANDER R; LILG C; LEPPERDINGER G; PLAS E; BERGER P, "Profiling molecular targets of TGF-betal in prostate fibroblast-to-myofibroblast transdifferentiation", MECHANISMS OF AGEING AND DEVELOPMENT, (2005), vol. 126, no. 1, pages 59 - 69
	- WESCHE J; HAGLUND K; HAUGSTEN EM, "Fibroblast growth factors and their receptors in cancer", THE BIOCHEMICAL JOURNAL, (2011), vol. 437, no. 2, pages 199 - 213
	- LOHELA M; BRY M; TAMMELA T; ALITALO K, "VEGFs and receptors involved in angiogenesis versus lymphangiogenesis", CURRENT OPINION IN CELL BIOLOGY, (2009), vol. 21, no. 2, pages 154 - 165
	- ISSA A; LE TX; SHOUSHTARI AN; SHIELDS JD; SWARTZ MA, "Vascular endothelial growth factor-C and C-C chemokine receptor 7 in tumor cell-lymphatic cross-talk promote invasive phenotype", CANCER RESEARCH, (2009), vol. 69, no. 1, pages 349 - 357
	- WANG Z; AHMAD A; LI Y; KONG D; AZMI AS; BANERJEE S; SARKAR FH, "Emerging roles of PDGF-D signaling pathway in tumor development and progression", BIOCHIMICA ET BIOPHYSICA ACTA, (2010), vol. 1806, no. 1, pages 122 - 130
	- LAM CT; YANG ZF; LAU CK; TAM KH; FAN ST; POON RT, "Brain-derived neurotrophic factor promotes tumorigenesis via induction of neovascularization: implication in hepatocellular carcinoma", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, (2011), vol. 17, no. 10, pages 3123 - 3133
	- KRAMER F; STOVER T; WARNECKE A; DIENSTHUBER M; LENARZ T; WISSEL K, "BDNF mRNA expression is significantly upregulated in vestibular schwannomas and correlates with proliferative activity", JOURNAL OF NEURO-ONCOLOGY, (2010), vol. 98, no. 1, pages 31 - 39
	- LUTOLF MP; LAUER-FIELDS JL; SCHMOEKEL HG; METTERS AT; WEBER FE; FIELDS GB; HUBBELL JA, "Synthetic matrix metalloproteinase-sensitive hydrogels for the conduction of tissue regeneration: engineering cell-invasion characteristics", PROC NATL ACAD SCI USA, (2003), vol. 100, no. 9, pages 5413 - 5418
	- EHRBAR M; RIZZI SC; HLUSHCHUK R; DJONOV V; ZISCH AH; HUBBELL JA; WEBER FE; LUTOLF MP, "Enzymatic formation of modular cell-instructive fibrin analogs for tissue engineering", BIOMATERIALS, (2007), vol. 28, no. 26, pages 3856 - 3866
	- MOSESSON MW, "Fibrinogen and fibrin structure and functions", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (2005), vol. 3, no. 8, pages 1894 - 1904
	- MARTINO MM; MOCHIZUKI M; ROTHENFLUH DA; REMPEL SA; HUBBELL JA; BARKER TH, "Controlling integrin specificity and stem cell differentiation in 2D and 3D environments through regulation of fibronectin domain stability", BIOMATERIALS, (2009), vol. 30, no. 6, pages 1089 - 1097
	- EHRBAR M; RIZZI SC; SCHOENMAKERS RG; MIGUEL BS; HUBBELL JA; WEBER FE; LUTOLF MP, "Biomolecular hydrogels formed and degraded via site-specific enzymatic reactions", BIOMACROMOLECULES, (2007), vol. 8, no. 10, pages 3000 - 3007
	- HANFT JR; POLLAK RA; BARBUL A; VAN GILS C; KWON PS; GRAY SM; LYNCH CJ; SEMBA CP; BREEN TJ, "Phase I trial on the safety of topical rhVEGF on chronic neuropathic diabetic foot ulcers", J WOUND CARE, (2008), vol. 17, no. 1, pages 30 - 32,34-37
	- ROBSON MC; PHILLIPS TJ; FALANGA V; ODENHEIMER DJ; PARISH LC; JENSEN JL; STEED DL, "Randomized trial of topically applied repifermin (recombinant human keratinocyte growth factor-2) to accelerate wound healing in venous ulcers", WOUND REPAIR REGEN, (2001), vol. 9, no. 5, pages 347 - 352
	- ROBSON MC; PHILLIPS LG; LAWRENCE WT; BISHOP JB; YOUNGERMAN JS; HAYWARD PG; BROEMELING LD; HEGGERS JP, "The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores", ANN SURG, (1992), vol. 216, no. 4, pages 401 - 406
	- ROBSON MC; PHILLIPS LG; THOMASON A; ROBSON LE; PIERCE GF, "Platelet- derived growth factor BB for the treatment of chronic pressure ulcers", LANCET, (1992), vol. 339, no. 8784, pages 23 - 25
	- SULLIVAN SR; UNDERWOOD RA; GIBRAN NS; SIGLE RO; USUI ML; CARTER WG; OLERUD JE, "Validation of a model for the study of multiple wounds in the diabetic mouse (db/db", PLAST RECONSTR SURG, (2004), vol. 113, no. 3, pages 953 - 960
	- DAVIDSON JM, "Animal models for wound repair", ARCH DERMATOL RES, (1998), vol. 290, pages I - 11
	- CHAN RK; LIU PH; PIETRAMAGGIORI G; IBRAHIM SI; HECHTMAN HB; ORGILL DP, "Effect of recombinant platelet-derived growth factor (Regranex) on wound closure in genetically diabetic mice", J BURN CARE RES, (2006), vol. 27, no. 2, pages 202 - 205
	- GALIANO RD; TEPPER OM; PELO CR; BHATT KA; CALLAGHAN M; BASTIDAS N; BUNTING S; STEINMETZ HG; GURTNER GC, "Topical vascular endothelial growth factor accelerates diabetic wound healing through increased angiogenesis and by mobilizing and recruiting bone marrow-derived cells", AM J PATHOL, (2004), vol. 164, no. 6, pages 1935 - 1947
	- HOLLINGER JO; HART CE; HIRSCH SN; LYNCH S; FRIEDLAENDER GE, "Recombinant human platelet-derived growth factor: biology and clinical applications", J BONE JOINT SURG AM, (2008), vol. 90, no. 1, pages 48 - 54
	- MUSCHLER GF; RAUT VP; PATTERSON TE; WENKE JC; HOLLINGER JO, "The design and use of animal models for translational research in bone tissue engineering and regenerative medicine", TISSUE ENG PART B REV, vol. 16, no. 1, pages 123 - 145
	- HOLLINGER JO; KLEINSCHMIDT JC, "The critical size defect as an experimental model to test bone repair materials", J CRANIOFAC SURG, (1990), vol. 1, no. 1, pages 60 - 68
	- SCHMOEKEL HG; WEBER FE; SCHENSE JC; GRATZ KW; SCHAWALDER P; HUBBELL JA, "Bone repair with a form of BMP-2 engineered for incorporation into fibrin cell ingrowth matrices", BIOTECHNOL BIOENG, (2005), vol. 89, no. 3, pages 253 - 262
	- GAUTSCHI OP; FREY SP; ZELLWEGER R, "Bone morphogenetic proteins in clinical applications", ANZ J SURG, (2007), vol. 77, no. 8, pages 626 - 631
	- JONES LL; OUDEGA M; BUNGE MB; TUSZYNSKI MH, "Neurotrophic factors, cellular bridges and gene therapy for spinal cord injury", THE JOURNAL OF PHYSIOLOGY, (2001), vol. 533, pages 83 - 89
	- ANDREWS MR; CZVITKOVICH S; DASSIE E; VOGELAAR CF; FAISSNER A; BLITS B; GAGE FH; FFRENCH-CONSTANT C; FAWCETT JW, "Alpha9 integrin promotes neurite outgrowth on tenascin-C and enhances sensory axon regeneration", THE JOURNAL OF NEUROSCIENCE: THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, (2009), vol. 29, no. 17, pages 5546 - 5557
	- TYSSELING-MATTIACE VM; SAHNI V; NIECE KL; BIRCH D; CZEISLER C; FEHLINGS MG; STUPP SI; KESSLER JA, "Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury", THE JOURNAL OF NEUROSCIENCE: THE OFFICIAL JOURNAL OF THE SOCIETY FOR NEUROSCIENCE, (2008), vol. 28, no. 14, pages 3814 - 3823
	- SHARP J; FRAME J; SIEGENTHALER M; NISTOR G; KEIRSTEAD HS, "Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants improve recovery after cervical spinal cord injury", STEM CELLS, (2010), vol. 28, no. 1, pages 152 - 163

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p